



ELMMB Formulary Update

April 2018

Subscribe Now

And be one of the first to know...

BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- **Fulvestrant** – untreated locally advanced or metastatic oestrogen-receptor positive breast cancer – NOT recommended as an option in [NICE TA503](#)
- **Intrabeam radiotherapy** – Adjuvant treatment of early breast cancer – NOT recommended as an option in [NICE TA501](#)
- **Lesinurad** – chronic hyperuricaemia in people with gout – NOT recommended as an option by [NICE TA506](#)

RED traffic light - Primary care prescribers should not be asked to prescribe (** denotes NHS England Commissioned)

- **Akynzeo®** - 2nd line anti-emetic for use with moderately & highly emetogenic cancer chemotherapy.
- **Pirfenidone**** – chronic idiopathic pulmonary fibrosis – recommended option in [NICE TA504](#)
- **Ceritinib**** - untreated ALK-positive non-small-cell lung cancer – an option in [NICE TA500](#)
- **Nifedipine drops** – Raynaud’s syndrome in children. Approved for use by paediatric consultants.
- **Ixazomib with lenalidomide & dexamethasone**** - relapsed or refractory multiple myeloma an option in NICE TA505 (Cancer Drugs Fund)
- **Sofosbuvir-velpatasvir-voxilaprevir**** chronic hepatitis c – an option in [NICE TA507](#)
- **Golimumab** – non-radiographic axial spondyloarthritis an option in [NICE TA497](#)
- **Lenvatinib**** with everolimus for previously treated advanced renal cell carcinoma an option in [NICE TA498](#)
- **Ibrutinib**** - relapsed or refractory mantle cell lymphoma – an option in [NICE TA502](#)
- **Gelcaprevir-pibrentasvir**** - chronic hepatitis c – an option in [NICE TA499](#)

AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **Ciclosporin eye drops (Ikervis®)** - changed to AMBER from RED. To be prescribed by brand – Ikervis®
- **Midazolam maleate (Epistatus®)** oromucosal soln **10mg/mL** licensed product for use in children & adolescents aged 10 to less than 18 years

Guidelines

- [Camouflage Creams and Powders Position Statement](#)
- [Rheumatoid Arthritis High Cost Drugs Pathway](#)
- [DVT Primary Care Pathway](#)
- [Denosumab Position Statement](#)
- **Bisphosphonates** for Treating Osteoporosis – [NICE TA464 updated](#)
- [Antihyperglycaemic Therapy in adults with type 2 diabetes](#)
- [Specialist Infant Formulary Feeds Guideline – updated](#)
- **Raloxifene** for the primary prevention of osteoporotic fragility fractures in postmenopausal women – [NICE TA160 updated](#)
- [Axial Spondyloarthritis Pathway](#)
- [Dementia Medicines Information Sheet](#)
- [Erectile Dysfunction Guidelines – updated](#)
- **Raloxifene & Teriparatide** for the secondary prevention of osteoporotic fragility fractures in postmenopausal women – [NICE TA 161 updated](#)

Other

- [Medicines Management Board Minutes June 2016](#)
- [Drug Safety Updates](#)
- [Nice Bites](#)
- [Prescribing Hot Topics](#)
- [Adult Social Care Training Programme 2018](#)
- [Training for Care Home Staff](#)
- [E learning hub](#)